Categories: Health

FDA Approves Donanemab for Early Symptoms of Alzheimer’s Disease



The approval follows positive data from the Phase 3 TRAILBLAZER-ALZ 2 clinical trial. According to Eli Lilly and Company, donanemab may help eliminate excessive amyloid plaque buildup and slow the progression of impairment related to a person’s ability to process new information or remember important dates, among other things.

The U.S. Food and Drug Administration (FDA) has approved the use of donanemab (350 mg/20 mL, monthly intravenous injection) from Eli Lilly and Company to treat adults with early-stage Alzheimer’s disease symptoms. This indication includes people… + more


Eli Lilly and Company Collaborates with OpenAI to Develop New Antimicrobial Drugs

The alliance will enable the use of generative artificial intelligence to develop personalized technologies to combat drug-resistant pathogens. + read more

QuickPen® preloaded with tirzepatide, which helps fight obesity and diabetes

The KwikPen is a pre-filled, multi-dose pen. It was first introduced to the market by Lilly in 2008 and is already used to administer various diabetes medications around the world. + read more

Mirikizumab Shows Promising Efficacy in Crohn’s Disease

The VIVID-1 study by Eli Lilly and Company shows that mirikizumab provides significant improvements in patients with Crohn’s disease, demonstrating efficacy in both bio-naive and treatment-naive patients. + read more

New agreement between Organon and Lilly to market two migraine drugs in Europe

Organon will have sole responsibility for the distribution and commercialization of Emgality® (galcanezumab) and RAYVOW™ (lasmiditan) in Europe, leveraging its commercial expertise in central nervous system diseases. + read more

Positive results of mirikizumab in moderate to severe Crohn’s disease

Results from the VIVID-1 study after 52 weeks of treatment demonstrate the efficacy of mirikizumab in achieving clinical remission and endoscopic response in patients with moderate to severe Crohn’s disease + read more

Progression of Pirtobrutinib in Adult Patients with CLL or PCLCL Pretreated with BTK Inhibitors

A publication in the New England Journal of Medicine (NEJM) provides additional clinical data to those presented at the 2022 American Society of Hematology (ASH) annual meeting + more.

Source link

Admin

Share
Published by
Admin

Recent Posts

Austin Butler Says Music Is ‘Therapy’

Austin Butler says playing music is like "therapy for the soul."The 31-year-old actor plays Elvis…

7 mins ago

A guide to France’s second round of elections that could bring Le Pen’s far right to power

This Sunday, July 7, from 8:00 p.m., Europe will resolve its doubts. The far-right National…

10 mins ago

Madrid to buy over 1.5 million flu vaccines for 2024 campaign

The Community of Madrid has secured the purchase of more than 1.5 million influenza vaccines…

12 mins ago

NEW LOS ARCOS | This will be the new Los Arcos shopping center: bowling, new brands and new restaurants.

This is what the new Los Arcos will look like after the renovation: bowling, new…

13 mins ago

What is Amazon Unified Code and Why Do You Need It Now?

If you have ever shopped at Amazonyou are most likely familiar with the North American…

18 mins ago

“The Bahamas has superstars, we have a lot to lose in individual talent”

He recalled, as in many other cases, the epic that always accompanies the "Family". With…

20 mins ago